Literature DB >> 6654521

Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.

P Flodgren, S Borgström, P E Jönsson, C Lindström, H O Sjögren.   

Abstract

With the aim of potentiating the anti-tumour effect of interferon in metastatic malignant melanoma by concomitant inhibition of suppressor T cells, oral cimetidine (histamine-2 receptor antagonist) medication was added to interferon (HuIFN-alpha(Le] therapy in a series of 20 patients. While no objective tumour responses were recorded with interferon treatment alone administered intramuscularly or intratumorally, six patients had objective tumour regressions on subsequent combined therapy. Five out of eight patients with metastases confined to skin and subcutaneous tissue had complete tumour regressions while one patient with skin and lung metastases achieved an extensive partial regression of the skin tumour and a complete roentgenological regression of the lung metastasis. Three additional patients attained a stable disease status for prolonged periods of time. Histopathological examinations confirmed disappearance and/or degeneration of melanoma cells and demonstrated a marked lymphocyte infiltration in tumour sites of the patients with objective tumour regression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6654521     DOI: 10.1002/ijc.2910320603

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Up-regulation of histidine decarboxylase expression and histamine content in B16F10 murine melanoma cells.

Authors:  Steven C Davis; Sheena Clark; J Robert Hayes; Todd L Green; Carl A Gruetter
Journal:  Inflamm Res       Date:  2010-07-18       Impact factor: 4.575

Review 2.  Mast cell polymorphisms. Present concepts, future directions.

Authors:  D Befus; H Fujimaki; T D Lee; M Swieter
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

3.  The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

Authors:  N Lahat; B Alexander; D R Levin; B Moskovitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis.

Authors:  Toshiaki Kinouchi; Junichi Sakamoto; Taiji Tsukamoto; Hideyuki Akaza; Yoshinobu Kubota; Seiichiro Ozono; Hiroshi Kanetake; Tetsuo Taguchi; Toshihiko Kotake
Journal:  J Cancer Res Clin Oncol       Date:  2006-04-04       Impact factor: 4.553

Review 6.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study.

Authors:  M E Marshall; K Butler; J Cantrell; C Wiseman; L Mendelsohn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.

Authors:  M N Saarloos; N K Khoo; P K Lala
Journal:  Clin Exp Metastasis       Date:  1993-05       Impact factor: 5.150

9.  Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

Authors:  A M Eggermont; W Weimar; B Tank; A M Dekkers-Bijma; R L Marquet; J S Lameris; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Complete remission in a patient with acute myelogenous leukemia treated with leukocyte alpha-interferon and cimetidine.

Authors:  J Ankerst; R Fäldt; P G Nilsson; P Flodgren; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.